Title: Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
Authors: TAUBER RFEUERECKER BENEDIKTKNORR KARINABEHESHTI ASEIDL C.BRUCHERTSEIFER FRANKRETZ MWEBER WOLFGANGGSCHWEND J.E.MORGENSTERN ALFREDEIBER MATTHIAS
Citation: UROLOGE vol. 58 no. Suppl 1 p. S105
Publisher: SPRINGER HEIDELBERG
Publication Year: 2019
JRC N°: JRC116164
ISSN: 0340-2592 (online)
URI: https://publications.jrc.ec.europa.eu/repository/handle/JRC116164
DOI: 10.1007/s00120-019-1018-y
Type: Articles in periodicals and books
Abstract: Despite the approval of several new agents metastatic castration resistant prostate cancer is still a major medical challenge. The beta-emitting Lu-177-PSMA radioligand therapy (RLT) is a new option but its antitumor effect can decrease over time. The aim of this retrospective analysis was to investigate safety and efficacy of the alpha emitting Ac-225-PSMA-617 RLT in mCRPC after Lu-177-PSMA failure.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.